Dual therapy with corticosteroid ablates the beneficial effect of dp2 antagonism in chronic experimental asthma

HIGHLIGHTS

• What: Using a preclinical model of chronic experimental asthma, the authors demonstrate that rhinovirus-induced exacerbations increase PGD2 release, mucus production, transforming growth factor (TGF)-β1 and type-2 inflammation. The authors demonstrate that DP2 antagonism resolves ASM remodelling via PGD2/DP1-mediated upregulation of IFN-γ expression, and that dual DP2 antagonism/corticosteroid therapy, as often occurred in the human trials, impairs the efficacy of DP2 antagonism by suppressing endogenous PGD2 and IFN-γ production.
• Who: Md Ashik Ullah from the (UNIVERSITY) have published the paper: Dual therapy with corticosteroid ablates the beneficial effect of DP2 . . .
  

   

  

  If you want to have access to all the content you need to log in!

  Thanks :)

  Username or E-mail:

  If you don't have an account, you can create one here.